March 22, 2019

Growing Number of Eye Care Professionals and Patients Turn to the Only Contact Lens Designed to Help with Eye Tiredness and Dryness Associated with Digital Eye Fatigue1

PLEASANTON, Calif., March 22, 2019—New industry data reveals that more than 40 percent of prescriptions for CooperVision Biofinity Energys® contact lenses are for new contact lens wearers, indicating that the innovative product has quickly become a new fit lens of choice for U.S. eye care professionals (ECPs).2 Likewise, the number of practices fitting Biofinity Energys has increased 25 percent over the past year.


In a world where prolonged digital device use is an everyday occurrence, ECPs and their patients are increasingly realizing the usefulness of CooperVision Biofinity Energys®—the only contact lenses designed to help with eye tiredness and dryness associated with digital eye fatigue.1


“I believe that patients who do a lot of near work on digital devices can benefit from Biofinity Energys®. These days, that can be anyone,” said Ross Shoter, OD, who practices at MyEyeDr. in Bethesda, Md. “Regardless of whether a patient is in school, works a desk job, or uses digital devices for fun, I fit them in Biofinity Energys® to help reduce some symptoms of digital eye fatigue, like eye tiredness and dryness, and provide all-day comfort—which is particularly important for new wearers.”


More than 90 percent of adults use digital devices for two or more hours per day, and more than 50 percent of 18-29 year olds admit to spending nine or more hours per day on digital devices.3 Biofinity Energys® contact lenses with Digital Zone Optics® lens design combine breakthrough optical properties with an advanced moisture-retaining polymeric material to keep eyes feeling comfortable during digital device use.


The lenses’ multiple aspheric curves distribute power evenly, resulting in more positive power across the entire optic zone, so wearers can change focus from on-screen to off-screen and back with less effort. A study revealed that patients wearing CooperVision Biofinity Energys® contact lenses experienced less change in accommodative microfluctuations and the lenses may help reduce ciliary muscle stress during digital device use.4


According to recent research, 87 percent of wearers agreed that Biofinity Energys® contact lenses are better for the demands of their lifestyles versus their previous contact lenses, and 94 percent said that Biofinity Energys® contact lenses met or exceeded their expectations.5


“Since the introduction of this breakthrough lens, CooperVision has partnered with eye care professionals to increase awareness of the prevalence of digital eye fatigue and its impact on today’s patients,” said Michele Andrews, OD, Senior Director of Professional and Academic Affairs, North America, CooperVision. “When fitting a patient in a monthly sphere contact lens, it is difficult to identify a reason not to reach for Biofinity Energys®. There are so many people who stand to benefit from this technology in today’s digital world; it’s important to fit them in innovative technology to meet their lifestyles right from the start.”


Biofinity Energys® lenses are available in the same material (comfilcon A, 48% water content) and parameter range as Biofinity® sphere lenses, with an 8.6 mm base curve, 0.08 mm center thickness at -3.00D, and 14.0 mm diameter in sphere powers from +8.00 to -12.00. The Dk/t of Biofinity Energys™ is also the same as Biofinity® sphere (160 at -3.00D).


For more information, please visit


# # #


1 US monthly single vision lens

2 US industry data on file, 2018
3 YouGov; Eye Fatigue Research 2016: Data on file
4 Based on a statistically significant difference of the mean change of Accommodative Microfluctuations and when compared to Biofinity sphere after reading on an iPhone for 20 minutes.
5 CVI data on file, 2018. Online survey Biofinity Energys® CL wearers, USA.

About CooperVision

CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit


About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in Pleasanton, CA, Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit


Media Contact

Mike McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision, Inc. or +1-585-545-1815